Cyclosporine (CsA) dose adjustments based on. C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective
|
|
- Phebe Dixon
- 5 years ago
- Views:
Transcription
1 REVIEW C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective Federico Villamil 1 and Stephen Pollard 2 Adjusting cyclosporine (CsA) dose based on blood concentration at 2 hours after dose (C 2 ) has been shown in prospective clinical trials to reduce the risk of rejection compared with conventional trough monitoring. In addition, it provides equivalent efficacy to tacrolimus in liver transplant patients, with a favorable safety profile. Target C 2 should be defined on an individual basis depending on adjunctive therapy and the level of exposure required. It appears less critical to achieve target C 2 in the first few days after liver transplantation than was previously believed. Achieving target C 2 exposure in the initial period after transplant requires that changes in the proportion of cyclosporine absorbed from the gut be taken into account to avoid risk of overexposure. In addition, if a starting dose of mg/day is used, it is advisable to delay increasing the dose until a trend in C 2 level indicates this to be necessary. Immediate dose reduction is required if C 2 exceeds target range. In patients with low C 2 values, cyclosporine concentration at a later time point should be measured to establish whether the patient is a poor absorber or a delayed absorber of C 2, and dose adjustments should be undertaken accordingly. In conclusion, this more flexible approach to C 2 monitoring allows the dose of cyclosporine to be individualized effectively for each patient, which results in significant efficacy benefits while minimizing the risk of toxicity. (Liver Transpl 2004;10: ) Cyclosporine (CsA) dose adjustments based on blood concentration at 2 hours after dose (C 2 ) have been shown to allow more sensitive individualization of drug exposure in transplant recipients than conventional trough (C 0 ) monitoring, 1 3 and many centers worldwide now routinely monitor CsA using C 2 levels. Recommendations for the implementation of C 2 monitoring were developed on the basis of early experience 4 and have provided guidance to transplant clinicians in terms of CsA dose adjustments and C 2 target ranges. Since that time, C 2 monitoring of CsA has been investigated further in large prospective trials, 5,6 and familiarity with C 2 monitoring in the clinical setting has grown. The knowledge gained from this additional experience offers the opportunity to reassess initial recommendations for the implementation of C 2 monitoring and to identify potential refinements in the liver transplant population. This review addresses the use of C 2 monitoring in the liver transplant patient during the early period after transplantation, based on an evaluation of the available data, and proposes an updated algorithm for CsA dose adjustments based on C 2 monitoring. Why Use C 2 Monitoring in Liver Transplantation? A landmark study by Grant et al. in demonstrated that CsA exposure over the first 6 hours after dose correlated closely with freedom from rejection in de novo liver transplant patients. Similarly, peak concentration correlated well with risk of rejection, although C 0 was not an accurate predictor of rejection risk. Time to peak concentration was found to occur at close to 2 hours after dose, such that C 2 could be regarded as a surrogate marker for peak concentration. When the relationship between C 2 and CsA exposure (area under the curve for the first six hours post-dose [AUC 0 6 ]) was analyzed, C 2 correlated closely with AUC 0 6 (r 0.93). Similarly, C 2 correlated more closely with CsA exposure than trough level in maintenance liver transplant recipients. 3 These results consistently indicated that C 2 monitoring is a more effective strategy for measuring CsA exposure than C 0 in liver transplantation and prompted two multicenter, prospective, randomized trials in which de novo liver transplant recipients receiving Neoral (CsA microemulsion, Novartis Pharma AG, Basel, Switzerland) were managed by C 2 monitoring Abbreviations: AUC 0 6, area under the curve for the first six hours post-dose; AUC 0 12, area under the curve for the first twelve hours post-dose; C 0, trough blood concentration; C 2, blood concentration at 2 hours after dose; C 4, blood concentration at 4 hours after dose; C 6, blood concentration at 6 hours after dose; CsA, cyclosporine; ME, microemulsion; MMF, mycophenolate mofetil. From the 1 Liver Unit, Fundacion Favoloro, Avenida Belgrano 1782, (C1093AAS), Buenos Aires, Argentina; and 2 St James s University Hospital, Beckett Street, Leeds, UK LS9 7TF. Address reprint requests to Professor Federico Villamil, Liver Unit, Fundacion Favoloro, Avenida Belgrano 1782 (C1093AAS), Buenos Aires, Argentina; Telephone: ; FAX: ; fvillamil@ffavaloro.org Copyright 2004 by the American Association for the Study of Liver Diseases Published online in Wiley InterScience ( DOI lt Liver Transplantation, Vol 10, No 5 (May), 2004: pp
2 578 Villamil and Pollard Table 1. Early C 2 Target Ranges and Incidence of BPAR for Trials of the Neoral Formulation of CsA Conducted in de Novo Liver Transplant Recipients Immunosuppressive Regimen C 2 Target Range 0 3 Months After Transplant (ng/ml) Incidence of BPAR at 3 Months CsA steroids azathioprine % CsA steroids azathioprine % CsA basiliximab (no steroids) % Abbreviations: BPAR, biopsy-proven acute rejection; CsA, cyclosporine. (i.e., dose adjustments were made on the basis of C 2 levels). The first trial compared conventional C 0 monitoring with C 2 monitoring in 307 patients. 5 At 3 months, the incidence of biopsy-proven acute rejection was lower with C 2 monitoring (24% vs 32% with C 0 monitoring), and the proportion of biopsy-proven episodes graded moderate or severe was significantly lower in the C 2 -monitored group (47% vs 73%, P.01). The incidence and severity of adverse events was similar in both arms. More recently, the LIS2T trial compared C 2 monitoring of CsA vs tacrolimus with C 0 monitoring in 499 de novo liver transplant recipients over the first 6 postoperative months. 6 An interim analysis of 300 patients showed that the incidence of biopsy-proven acute rejection by 3 months was 28% among the CsA patients and 27% in those receiving tacrolimus (P ns). The overall safety profile was equivalent in both treatment arms. However, patients receiving CsA had a significantly lower incidence of new-onset diabetes mellitus and diarrhea. Using C 2 monitoring of CsA in a steroid-free regimen also has been shown to result in a low rate of rejection (14% at 3 months) among de novo liver transplant patients receiving the anti-cd25 antibody basiliximab. 7 Overall, the efficacy of C 2 monitoring is excellent, with rejection rates ranging from 14% to 28% (Table 1), 5 7 and is superior to results previously reported in studies using CsA C 0 monitoring. 8,9 Moreover, in maintenance patients previously managed by C 0 monitoring, adoption of C 2 monitoring can identify patients overexposed to CsA. The resulting dose reductions can lead to significant improvements in renal function, blood pressure, and serum cholesterol. 3,10 Individualizing Target C 2 Range Initially, it was thought that the same C 2 range could be applied to all liver transplant patients, irrespective of particular patient characteristics or concomitant medication. There is a growing realization, however, that to provide the required level of exposure to CsA, the target C 2 range should be adjusted according to the patient s risk of graft loss or predilection to adverse events and the intensity of adjunctive immunosuppressive therapy. Guidance as to appropriate target levels is available from completed trials of C 2 monitoring in liver transplantation (Table 1). Within a triple regimen comprising CsA ME and steroids with or without azathioprine, a target range of ng/ml for the first 3 months after transplant achieved a 22% rate of acute rejection 5 ; a slightly lower target range ( ng/ml) in a separate study resulted in a 3-month rejection rate of 28%. 6 Target levels should be reduced progressively over the first year after transplant, and it has been proposed that a target level of 800 ng/ml (range ng/ml) after 6 months and 600ng/mL (range ng/ml) after 1 year may be appropriate in patients receiving CsA and steroids. 4 Among 104 liver transplant patients who initially received steroids with or without azathioprine and who were managed using C 2 monitoring, mean C 2 level was 763 ng/ml at 1 year after transplant, the incidence of acute rejection was 27%, mean serum creatinine was 118 mol/l, and only 10% of patients still required azathioprine. 11 Others have used a target range of ng/ml in patients more than 1 year after transplant maintained on CsA. 3 In patients receiving mycophenolate mofetil (MMF) because of an identified need for increased immunosuppression, it may be appropriate to use the same C 2 target for MMF-treated patients as for those receiving azathioprine or dual therapy unless the MMF dose is high. When MMF is initiated to reduce CsA exposure in cases of CsA-related toxicity, reduced CsA dosing and C 2 targets can be attempted. However, no trials of C 2 monitoring have been carried out in MMFtreated liver transplant recipients to date or, indeed, those given sirolimus or everolimus. Relative Importance of Attaining C 2 Target Early The effect of attaining target C 2 level early in liver transplant recipients has been assessed in a comparative study of C 2 vs C 0 monitoring. 5 In this study, a small number of patients (n 16) reached the C 2 target range of ng/ml by day 3, and incidence of
3 C 2 Monitoring of Cyclosporine 579 rejection in this group was only 13%. The incidence was 26% among those attaining target C 2 by day 7 and 34% for those patients who reached target by day 10. In the LIS2T study, in contrast, there was little difference in risk of rejection, regardless of when C 2 range was achieved. It is important to note that the overall incidence of biopsy-proven acute rejection using CsA C 2 monitoring in these studies (22 28%) was low compared with the literature (36 59%). 8,9,12 This is despite the fact that one quarter of patients in the C 2 vs C 0 study and one third of those in the LIS2T trial did not reach C 2 target until after day 7. It thus appears less critical to achieve target C 2 by day 3 or 5 after liver transplantation than had initially been believed. Variation in Cyclosporine Absorption in the Early Posttransplant Period Absorption of the Neoral formulation of CsA is relatively independent of bile flow and food consumption, 13 and once a patient is stabilized on a dose, it generally does not need to be amended unless the target exposure changes. However, during the initial posttransplant period and particularly during the first few days the amount of CsA absorbed from a given dose can alter markedly. A number of factors can contribute to this situation, for example, recovery from paralytic ileus with consequent improvement of CsA absorption from the gut, improvement in graft function and cholestasis, or clamping of external biliary drainage. Data from 250 patients managed by C 2 monitoring of CsA within the LIS2T study demonstrate how C 2 levels evolve during the first few weeks after transplant. The mean ratio of C 2 achieved per 1 mg/kg/day over the first 3 months after transplant is shown in Fig There was a pronounced increase in the proportion of CsA measured in blood at 2 hours after dose, rising more than 4-fold by the end of the first month after transplantation. By the end of the second month, however, levels stabilized. Interestingly, it appears to take longer for absorption of CsA to stabilize in liver transplant recipients compared with renal transplant patients, in whom there is little change in the proportion of drug absorbed after the first month. In liver transplant patients, the time to peak concentration remains relatively stable in the early posttransplant period using the Neoral formulation of CsA, shortening only marginally from 2.2 hours at 10 days after transplant to 2.0 hours at 16 weeks. 1 This suggests that the increasing C 2 :dose ratio over this period is at least partially caused by a genuine improvement in absorption Figure 1. Mean blood concentration at 2 hours after dose (C 2 ) achieved per 1 mg/kg/day cyclosporine (CsA) microemulsion (ME) among 250 de novo liver transplant recipients during the first 3 months after transplant (Data on file, Novartis Pharma AG. Study COLO400A2412 [LIS2T]). from the gut, rather than solely a change in the shape of the absorption curve. Clearly, this change in the C 2 level achieved for a given dose must be taken into account when making dose adjustments early after transplant. Otherwise, improvements in absorption would risk the patient s overshooting target C 2 level unexpectedly if a dose increase is made at a time when absorption is improving quickly. Adjusting Dose of Cyclosporine Previously, it was recommended 4 that the dose of CsA be adjusted in direct proportion to the required change in C 2 level. However, this strategy assumes that a constant proportion of the CsA dose is absorbed at all time points, whereas, in fact, absorption improves markedly during the initial posttransplant period, as previously mentioned. Thus, calculating a dose increase in proportion to the required C 2 level could result in overshooting the C 2 target range if the change in dose coincides with a pronounced improvement in CsA absorption not accounted for when calculating the new dose. Alternatively, patients may remain below target despite a proportional increase in dose if they are poor or delayed absorbers of CsA (see The Patient With Low C 2 Values section later in this article) or if the initial dose of CsA they received was too low. To minimize the risk of overexposure or underexposure to CsA, the following approach appears reasonable: 1. Use an initial dose of CsA appropriate for the desired exposure level. For dual therapy or triple therapy
4 580 Villamil and Pollard Figure 2. Cyclosporine (CsA) dose and blood concentration at 2 hours after dose (C 2 ) levels in a patient taking part in the LIS2T study in whom changes in CsA absorption were taken into account during dose adjustments. Using a starting dose of 11 mg/kg/day, C 2 reached the maximum target value by day 3. The dose was then reduced to accommodate improving CsA absorption. Despite the patient s being within C 2 target on day 5, the clinician reduced the dose further on days 7 and 14, thus avoiding overshooting the C 2 target as CsA absorption continued to improve. with azathioprine, a starting dose of mg/kg/ day is suitable when patients can tolerate a full dose. Otherwise, a lower starting dose should be used and titrated upward on a daily basis as rapidly as possible, based on target levels and tolerability. 2. Measure C 2 level daily for the first week after transplant or until C 2 values stabilize. 3. Monitor C 2 levels to detect a trend before increasing the dose; usually this will require measurements from 3 consecutive days. Once a trend is established, adjust the dose accordingly if required, taking into account improving CsA absorption (Fig. 2) when determining the new dose. If the C 2 level exceeds target, reduce the dose immediately to avoid toxicity (Fig. 3). Figure 3. Cyclosporine (CsA) dose and blood concentration at 2 hours after dose (C 2 ) level in a patient taking part in the LIS2T study, in whom improving CsA absorption was not taken into account when adjusting dose. With a starting dose of 11 mg/kg/day, C 2 increased markedly on day 7 as CsA absorption improved, rising again by day 16 to the upper range of the C 2 target. However, dose was not reduced to take into account improving absorption, such that C 2 level exceeded target, resulting in renal dysfunction days (small arrow). The subsequent dose reduction was too late and too limited to avoid a second episode of renal dysfunction during days (large arrow). 4. Continue to monitor C 2 levels regularly once C 2 values have stabilized. In the in-patient setting, C 2 measurement 2 or 3 times a week is likely to be adequate. For outpatients, C 2 levels should be measured at each routine clinic visit, for example twice a week for the first 2 3 weeks after discharge then weekly for the first 2 months. Reduce the CsA dose if C 2 levels are above target. However, if a patient is below target, it may be useful to repeat the C 2 measurement a few days later for confirmation before increasing the dose if there are no signs of rejection. Once CsA absorption has stabilized, it becomes appropriate to increase the dose in direct proportion to the desired change in C 2 level.
5 C 2 Monitoring of Cyclosporine 581 Figure 4. Typical pharmacokinetic profile for a good absorber of cyclosporine (CsA), a poor absorber of CsA, and a delayed absorber of CsA. The license for CsA microemulsion states a maximum dose of mg/kg. Although in some patients, the physician may exceed this dose for specific reasons (e.g., in a patient shown to be a poor CsA absorber), keep in mind that liver transplant recipients given a dose of CsA above 20 mg/kg/day are at increased risk of CsA-related toxicity, particularly nephrotoxicity. It is unlikely that a dose greater than 20 mg/kg/day is necessary; patients who do not achieve C 2 target with these doses may be delayed absorbers of CsA (see the next section) and would be overexposed to CsA with any further increase in dose. The Patient With Low C 2 Values A proportion of patients do not show a trend toward achieving C 2 target ranges, despite appropriate dosing during the first week after transplant. There are 2 possible reasons for this. First, the patient may be a poor absorber of CsA; this may be an inherent characteristic that will persist over the long term. More commonly, it may be the result of short-term limited absorption caused by slow recovery of normal gastrointestinal and hepatobiliary function after surgery. Second, the patient may be a delayed absorber of CsA, that is, with a long time to peak concentration such that C 2 values remain low despite adequate total exposure to CsA (Fig. 4). Distinguishing between poor and delayed absorbers of CsA is critical because the management response differs. If a patient continues to show a low C 2 value by day 4 or 5 after transplant despite adequate CsA dose of between 10 and 15 mg/kg/day, blood CsA concentration should be measured at a later time point usually C 4 or C 6.IftheC 4 or C 6 value is lower than the C 2 value, or if it is similar, the patient is a poor absorber of CsA, and a higher dose of CsA may be appropriate without compromising safety up to a maximum of 20 mg/kg/day. The addition of another agent also may be helpful until the absorption of CsA reaches an appropriate level. In these poor absorbers of CsA, it is particularly important to monitor exposure closely, because a sudden improvement in absorption of CsA might result in overshooting the target and might require immediate dose reduction. If, however, the C 4 or C 6 value is higher than C 2, there is a late peak concentration, that is, the patient is a delayed absorber of CsA. In patients with this type of profile, the dose should be increased only with caution, and it is advisable to continue monitoring of both C 2, and to check CsA exposure at a later time point (e.g., C 4,C 6,or even C 0 ). Preliminary evidence suggests that delayed absorption may be a temporary phenomenon, at least in some patients. Therefore, repeated measurement at a later
6 582 Villamil and Pollard Figure 5. Proposed algorithm for blood concentration at 2 hours after dose (C 2 ) monitoring of cyclosporine (CsA) during the first 2 weeks after liver transplantation. Abbreviations: IS, immunosuppression; AUC 0 12, area under the curve for the first 12 hours post-dose. time point during follow-up will detect if a patient reverts to a more standard CsA absorption profile. Minor Dose Adjustments Over the duration of the 6-month LIS2T study, the mean number of dose adjustments per patient was 19 in the patients managed by CsA C 2 monitoring (range 1 62), compared with 16 with tacrolimus (range 1 58). 14 In some cases, the dose of CsA was repeatedly increased to a minor degree (e.g., 0.3 mg/kg/day or 5% of the total dose) then decreased to the same extent on successive days, which was unlikely to have affected C 2 values significantly. Given that patients absorption of CsA not only varies with time after transplant but also can be affected to a minor extent by food consumption 15 on a day-to-day basis, frequent, minor dose modifications are not likely to be helpful. As familiarity with C 2 monitoring increases, it is likely that the number of dose changes will decline with no penalty in terms of efficacy or safety. Implementation of C 2 Monitoring Early involvement of ward, clinic, and laboratory staff is important when adopting C 2 monitoring of CsA to ensure that samples are taken punctually and that results are reported promptly to allow for timely dose changes. There is a 15-minute window on either side of the 2-hour time point 16 during which samples provide adequate accuracy. For in-patients, it can be convenient to administer the dose of CsA-ME 2 hours earlier than when C 0 monitoring was used, such that the phlebotomist s schedule remains unchanged. Nursing staff should keep a record of the time that the CsA-ME dose is given to each patient, with the required time for C 2 sampling, and the phlebotomist should then record the exact actual time that the sample is taken. The laboratory should be informed of the expected C 2 range, such that laboratory staff can adopt and validate an appropriate dilution protocol. The assay system used does not need to be changed, and in contrast to C 0 monitoring, C 2 values are generally sufficiently consistent regardless of assay type because the level of CsA metabolites is lower with C 2 monitoring. Within our own units, staffing requirements did not increase as a result of adopting C 2 monitoring. Detailed recommendations have been developed for implementing C 2 monitoring 17 on the basis of the experience of several transplant centers. Conclusions C 2 monitoring allows the dose of CsA to be individualized according to the absorption characteristics of each patient, which results in significant efficacy benefits while minimizing the risk of toxicity. The evidence
7 C 2 Monitoring of Cyclosporine 583 now available indicates that C 2 monitoring should be adopted routinely in de novo liver transplant recipients immunosuppressed with CsA and that it can achieve low levels of rejection with a favorable safety profile. 6 Experience in recent clinical trials has led to refinements in early recommendations for dose management based on C 2 values. First, inflexible adoption of dose increases in direct proportion to the required increase in C 2 is likely to lead to overshooting of the C 2 target because of the concurrent improvement in CsA absorption that occurs after liver transplantation. Instead, dose increases should be delayed until day 5 if a full starting dose of mg/kg/day is used and should be undertaken when a trend in C 2 level is apparent. Any dose increase should take into account increasing absorption. Fig. 5 illustrates a proposed strategy for dose adjustments during the first 2 weeks after liver transplantation. Subsequently, C 2 levels (and probably C 4 or C 6 in delayed absorbers) should be monitored regularly, and the dose should be adjusted according to the trend observed to remain within the target range. Experience indicates that achieving C 2 target within the first 3 or 5 days after transplant may be less necessary than formerly believed, which supports a more cautious approach to dose increases during the early posttransplant period. In particular, it is not advisable to increase the dose beyond 20 mg/kg/day without good reason. In summary, as our understanding of C 2 monitoring of the Neoral formulation of CsA has grown, it has become clear that a more flexible approach to its implementation, incorporating individual differences in CsA absorption, will enable us to retain the excellent clinical outcomes reported to date while reducing risk of toxicity still further. References 1. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection. Transplantation 1999;67: Barkat O, Peaston R, Rai R, Talbot D, Manas D. Clinical benefit of monitoring cyclosporine C 2 and C 4 in long-term liver transplant recipients. Transplant Proc 2002;34: Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998;66: Levy G, Thervet E, Lake J, Uchida K on behalf of the CON- CERT group. Patient management by Neoral C 2 monitoring: an international consensus statement. Transplantation 2002; 73(suppl):S12 S Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C 2 ). Transplantation 2002;73: Villamil F, Ericzon BG, Risaliti A, Munn S, Cantisani G, Jones R, et al on behalf of the LIS2T Study Group. Efficacy and safety of cyclosporine microemulsion with C 2 monitoring versus tacrolimus in de novo liver transplant recipients [Abstract 314]. Liver Transplantation 2003:9:C Llado L, Figueras J, Xiol X, Torras J, Rafecas A, Lastra R, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infectious and metabolic complications [Abstract 315]. Liver Transpl 2003;9:C Otto M-G, Mayer AD, Clavien P-A, Cavallari A, Gunawardena KA, Mueller EA on behalf of the MILTON Study Group. Randomized trial of cyclosporine microemulsion (Neoral) versus conventional cyclosporine in liver transplantation. Transplantation 1998;66: O Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, and the UK and Republic of Ireland Liver Transplant Study. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised control trial. Lancet 2002;360: Levy GA, Smith R, O Grady C, Lilly LB, Girgrah N, Greig P, Grant DR. Long term follow up of maintenance liver transplant patients converted to C 2 cyclosporine using Neoral immunosuppression [Abstract]. Am J Transplant 2003;3(suppl 5):324(Abs 673). 11. Lake JR on behalf of the Neo-INT-O6 Study Group. Benefits of cyclosporin microemulsion (Neoral) C 2 monitoring are sustained at 1 year in de novo liver transplant recipients. Transplant Proc 2001;33: Mueller EA, Kallay Z, Kovarik JM, Richard F, Wiesinger O, Schmidt K, et al. Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. Transplantation 1995;60: Grant D, Rochon J, Levy G. Comparison of the long-term tolerability, pharmacodynamics and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Transplant Proc 1996;28: Data on file. Novartis Pharma AG. Study COLO400A2412 (LISZT). 15. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994;11: Kahan, BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002;24: Cole E, Midtvedt K, Johnston A, Pattison J, O Grady C. Recommendations for the implementation of Neoral C2 monitoring in clinical practice. Transplantation 2002; 73(Suppl):S19 22.
Cyclosporine absorption profiles in pediatric kidney and liver transplant patients
Pediatr Nephrol (2003) 18:1275 1279 DOI 10.1007/s00467-003-1260-8 ORIGINAL ARTICLE J. M. Kovarik Peter F. Hoyer Robert Ettenger Jeffrey Punch Marianne Soergel Cyclosporine absorption profiles in pediatric
More informationTARGET RANGE MAXIMUM OF CYCLOSPORINE BLOOD CONCENTRATION TWO HOURS POST DOSE IN STABLE LIVER TRANSPLANT PATIENTS*
EUROPEAN JOURNAL OF MEDICAL RESEARCH 139 Eur J Med Res (2006) 11: 139-145 I. Holzapfel Publishers 2006 TARGET RANGE MAXIMUM OF CYCLOSPORINE BLOOD CONCENTRATION TWO HOURS POST DOSE IN STABLE LIVER TRANSPLANT
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationDRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain
DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Silvio Sandrini Division and Chair of Nephrology University
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationS tefan Vítko 1 and Marek Ferkl 2. original article
http://www.kidney-international.org & 2010 International Society of Nephrology Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of and capsules in
More informationORIGINAL ARTICLE. Received March 14, 2007; accepted August 29, 2007.
LIVER TRANSPLANTATION 14:173-180, 2008 ORIGINAL ARTICLE A Randomized, Prospective, Pharmacoeconomic Trial of Neoral 2-Hour Postdose Concentration Monitoring Versus Tacrolimus Trough Concentration Monitoring
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationLothar Bernd Zimmerhackl
What works in current paediatric practice of off-label dose adjustment of adult doses? Lothar Bernd Zimmerhackl Medical University Innsbruck Austria AGAH Workshop: Pediatric Investigation Plan. Bonn 13-14.1.
More informationScottish Medicines Consortium
Scottish Medicines Consortium tacrolimus, 5mg/ml concentrate for infusion and 0.5mg, 1mg, 5mg hard capsules (Prograf ) No. (346/07) Astellas Pharma Ltd 12 January 2007 The Scottish Medicines Consortium
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationMonitoring of Blood Cyclosporine Concentration in Steroid-Resistant Nephrotic Syndrome
ORIGINAL ARTICLE Monitoring of Blood Cyclosporine Concentration in Steroid-Resistant Nephrotic Syndrome Masayo Naito, Takashi Takei, Aya Eguchi, Keiko Uchida, Ken Tsuchiya and Kosaku Nitta Abstract Objective
More informationLong-term cardiovascular risk in transplantation insights from the use of everolimus in heart transplantation
Nephrol Dial Transplant (2006) 21 [Suppl 3]: iii9 iii13 doi:10.1093/ndt/gfl295 Long-term cardiovascular risk in transplantation insights from the use of everolimus in heart transplantation Howard Eisen
More informationGeneral Introduction. 1 general introduction 13
General Introduction In The Netherlands 13,000 patients suffer from end stage renal disease (ESRD), which left untreated inevitably results in death. Every year this number increases with approximately
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive
More informationProton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium
Proton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium S. Kofler, C. Wolf, Z. Sisic, J. Behr, M. Vogeser, M. Shipkova, B. Meiser, G. Steinbeck, B. Reichart,
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationRe: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)
January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf -/Advagraf -Based Immunosuppressive
More informationRenal Biopsy Findings in Children Receiving Long-Term Treatment with Cyclosporine A Given as a Single Daily Dose
Tohoku J. Exp. Med., Posttreatment 2006, 209, 191-196 Renal Biopsy Following Once-daily CsA Treatment 191 Renal Biopsy Findings in Children Receiving Long-Term Treatment with Cyclosporine A Given as a
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationLaboratory Monitoring of Cyclosporine Pre-dose Concentration (C 0 ) After Kidney Transplantation in Isfahan
IJMS Vol 28, No.2, June 2003 Original Article Laboratory Monitoring of Cyclosporine Pre-dose Concentration (C 0 ) After Kidney Transplantation in Isfahan Z. Tolou-Ghamari*, A.A. Palizban. Abstract Background:
More informationPanGraf Tacrolimus Capsules 0.5 / 1.0 / 5.0
For the use of a Nephrologist / Transplant Surgeon or a Hospital or a Laboratory only PanGraf Tacrolimus Capsules 0.5 / 1.0 / 5.0 DESCRIPTION Tacrolimus is a macrolide lactone with potent immunosuppressive
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482
Immunosuppressive e therapy for kidney transplant in children and young people Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 NICE 2018. All rights reserved. Subject
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationPharmacogenetics to tailor Drug Exposure and Outcomes in Kidney Transplantation
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 SCT Plenary 4 Thursday March 30, 2017 Pharmacogenetics to tailor Drug Exposure and Outcomes in Kidney Transplantation Dennis A. Hesselink
More informationTherapeutic drug monitoring
nep_730.fm Page 57 Friday, January 26, 2007 6:45 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology200712S15765MiscellaneousCalcineurin
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: TACROLIMUS Protocol number: CV 43
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: TACROLIMUS Protocol number: CV 43 Indications: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS.
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More information2017 BANFF-SCT Joint Scientific Meeting. Personalized Medicine in Liver Transplantation
2017 BANFF-SCT Joint Scientific Meeting Personalized Medicine in Liver Transplantation Miquel Navasa Liver Transplant Unit. Hospital Clínic. Barcelona. Barcelona, March 2017 Disclosures Consultant for
More informationReview Article The Role of mtor Inhibitors in Liver Transplantation: Reviewing the Evidence
Hindawi Publishing Corporation Journal of Transplantation Volume 2014, Article ID 845438, 45 pages http://dx.doi.org/10.1155/2014/845438 Review Article The Role of mtor Inhibitors in Liver Transplantation:
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationTherapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis
Mod Rheumatol (2011) 21:32 36 DOI 10.1007/s10165-010-0342-2 ORIGINAL ARTICLE Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis Koji Nagai Tohru Takeuchi
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationDoes the formulation of tacrolimus matter?
Does the formulation of tacrolimus matter? This promotional meeting has been fully funded and organised by Astellas Pharma Ltd and Astellas products will be discussed. PI can be found at the end of this
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationSupporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan
Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan Thomas Dumortier, Mick Looby Novartis Pharma AG, Basel, Switzerland EMA public workshop on extrapolation of
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER
More informationDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, USA
Trends in Transplantation Transplant. 2009;3:146-52 The Myth of Bioequivalence Heidi M. Schaefer and J. Harold Helderman Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center,
More informationCyclosporine Lymphocyte Maximum Level Monitoring in De Novo Kidney Transplant Patients: A Prospective Study
Cyclosporine Lymphocyte Maximum Level Monitoring in De Novo Kidney Transplant Patients: A Prospective Study AG Barbari, MA Masri, AG Stephan, B El Ghoul, S Rizk, N Mourad, GS Kamel, HE Kilani, AS Karam
More informationTACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver disease
Oxford Gastroenterology Unit Shared Care Protocol & Information for GPs TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationInduction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:1210-1214, 2006 ORIGINAL ARTICLE Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation Ashesh Shah, 1 Avinash Agarwal, 1 Richard Mangus,
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationImmunosuppressive Strategies in Liver Transplantation for Hepatitis C
Trends in Transplantation Transplant. 2010;4:78-85 Immunosuppressive Strategies in Liver Transplantation for Hepatitis C Timothy M. Clifford 1-3, Michael F. Daily 1,3 and Roberto Gedaly 1,3 1 UK HealthCare,
More informationIMMUNOSUPPRESSION. Background:
IMMUNOSUPPRESSION Tacrolimus Versus Cyclosporine Microemulsion for Heart Transplant Recipients: A Meta-analysis Fan Ye, MD, a Xiao Ying-Bin, MD, a Weng Yu-Guo, MD, b and Roland Hetzer, MD b Background:
More informationAljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department
More informationThe common premise for immunosuppressive
therapy update Current trends in immunosuppressive therapies for renal transplant recipients The common premise for immunosuppressive therapies in kidney transplantation is to use multiple agents to work
More informationMycophenolate Blood Level Monitoring: Recent Progress
American Journal of Transplantation 2009; 9: 1495 1499 Wiley Periodicals Inc. Minireview C 2009 The Author Journal compilation C 2009 The American Society of Transplantation and the American Society of
More informationModel-based dose adjustment in treatment personalization of immunosuppressive drugs
Model-based dose adjustment in treatment personalization of immunosuppressive drugs Pierre Marquet, MD, PhD INSERM Unit 850 University Hospital Limoges, France Treatment personalization «The right patient,
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More informationClinical decisions regarding immunosuppressive
PHARMACOLOGIC THERAPIES AND RATIONALES * Stuart D. Russell, MD ABSTRACT This article reviews evidence related to the use of induction therapy and longer-term combination immunosuppressive drug regimens
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationPharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation
Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation Caroline Monchaud and Pierre Marquet INSERM Unit 850, CHU Limoges, Univ Limoges, France. Word count (text only): 25132
More informationThis assessment report is based on evidence submitted by Astellas Pharma Ltd. on 18 January 2010.
AWMSG Secretariat Assessment Report Advice no. 0811 Tacrolimus (Advagraf ) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection
More informationKidney Dysfunction in the Recipients of Liver Transplants
Kidney Dysfunction in the Recipients of Liver Transplants Alan Wilkinson and Phuong-Thu Pham Key Points 1. Pretransplant kidney function is an important predictor of posttransplant kidney function. 2.
More informationLong-Term Effects of Calcineurin Inhibitors on Renal Function After Liver Transplantation
Trends in Transplant. 2008;2:129-34 Georges-Philippe Pageaux, et al.: Renal Function and Liver Transplantation Long-Term Effects of Calcineurin Inhibitors on Renal Function After Liver Transplantation
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationChapter 4 Section 24.7
Surgery Chapter 4 Section 24.7 Simultaneous Pancreas-Kidney (SPK), Pancreas-After-Kidney (PAK), And Pancreas-Transplant-Alone (PTA), And Pancreatic Islet Cell Transplantation Issue Date: February 5, 1996
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481
Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationvalganciclovir, 450mg tablets, 50mg/ml powder for oral solution (Valcyte ) SMC No. (662/10) Roche Products Ltd
valganciclovir, 450mg tablets, 50mg/ml powder for oral solution (Valcyte ) SMC No. (662/10) Roche Products Ltd 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationDiltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R
Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationProtein Kinase C Inhibitor Sotrastaurin in De Novo Liver Transplant Recipients: A Randomized Phase II Trial
American Journal of Transplantation 2015; 15: 1283 1292 Wiley Periodicals Inc. C copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13175
More informationSerum Cholesterol Changes in Long-Term Survivors of Liver Transplantation: A Comparison Between Cyclosporine and Tacrolimus Therapy
Serum Cholesterol Changes in Long-Term Survivors of Liver Transplantation: A Comparison Between Cyclosporine and Tacrolimus Therapy Ramón Charco,* Carme Cantarell, Victor Vargas,* Luis Capdevila, Jose
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: CICLOSPORIN Protocol number: CV 06
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: CICLOSPORIN Protocol number: CV 06 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS
More informationImmunosuppressive therapy after human lung transplantation
Eur Respir J 2004; 23: 159 171 DOI: 10.1183/09031936.03.00039203 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 CONTRIBUTIONS FROM THE EUROPEAN
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationSINCE the introduction of Imuran and
Cadaveric Renal Transplantation With Cyclosporin-A and Steroids T. R. Hakala, T. E. Starzl, J. T. Rosenthal, B. Shaw, and S. watsuki SNCE the introduction of muran and prednisone in 1961, and despite the
More informationEarly Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation
Trends in Transplantation Transplant. 2012;6:28-33 Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Hallvard Holdaas Department
More informationA review of absorption characteristics of microemulsion cyclosporine products over the last 2 years in Indian subjects S SINGH*, D R SHARMA**
A review of absorption characteristics of microemulsion cyclosporine products over the last 2 years in Indian subjects S SINGH*, D R SHARMA** Microemulsion based cyclosporine has demonstrated better absorption
More informationNIH Public Access Author Manuscript Res Commun Chem Pathol Pharmacol. Author manuscript; available in PMC 2010 October 18.
NIH Public Access Author Manuscript Published in final edited form as: Res Commun Chem Pathol Pharmacol. 1986 July ; 53(1): 137 140. EFFECT OF BILE ON CYCLOSPORINE ABSORPTION IN DOGS Raman Venkataramanan
More informationCyclosporin versus Tacrolimus for Liver Transplanted Patients
Western University Scholarship@Western Surgery Publications Surgery Department 2006 Cyclosporin versus Tacrolimus for Liver Transplanted Patients Elizabeth Haddad University of Western Ontario, ehaddad2@uwo.ca
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants
2017 CST-Astellas Canadian Transplant Fellows Symposium Management of Renal Dysfunction in Extra Renal Transplants Jeffrey Schiff, MD Dr. Jeffrey Schiff is an Assistant Professor of Medicine at the University
More information